Oulu-based iSTOC answers the need for testing large populations quickly and cost-efficiently with its mobile diagnostics solution for screening and mapping the spread of different infectious diseases, like Covid-19. The innovation is used with rapid tests that can detect antibodies from a small drop of blood. Test results are scanned with a smartphone and digitized.
iSTOC is now focusing on international markets. To stimulate the process of internationalisation, the company has recently established several promising partnerships in France, Brazil and the USA.
The company has started cooperation with CEMAG Care in France to develop better diagnostics and deliver IDA (immediate diagnostics and analytics) solutions around the globe.
In the United States, iSTOC is working with Acumen Health Intelligence, which has a US licence to pair the iSTOC software with its highly accurate antibody tests. iSTOC software provides multiple layers of oversight to mitigate the potential risk of test misinterpretation. First, the certified field technician and the patient can both view and interpret the result. Then, using the iSTOC app on a smartphone, a photo of the test is scanned in and the software accurately interprets the result as well. Then, a clinician (accessed virtually or in person) can confirm the result and build a care plan if necessary.
“Through our partnership with iSTOC, we have developed a comprehensive, turn-key COVID-19 testing solution. The innovative IDA platform, real-time analytics and interactive mapping provide vital testing data to our clients in both the public and private sectors. Together we are deploying practical, scalable, testing programs to slow the spread of COVID-19, reopen the workplace and revitalize the US economy,” stated Shawn Kelley, CEO of Acumen.
As part of the partnership in Brazil, iSTOC, Lifemed and Signove Tecnologia S/A are joining forces to improve the effectiveness of healthcare. With the iSTOC IDA platform, it will be possible to deliver a digital Point-of-Care solution for slowing down the spread of COVID-19 in Brazil. iSTOC is operating in Brazil also on another field; together with a national blood bank, the company is facilitating research and clinical trials.
iSTOC has developed a disruptive mobile solution IDA (immediate diagnostics and analytics), which is a holistic turnkey solution for Point of Care diagnostics, incl. infectious diseases, blood grouping, and reproductive health. iSTOC IDA is FDA and CE certified and compliant with both GDPR and HiPAA. iSTOC enables and follows WHO Guidelines for Infectious Disease Control Programs. The company is headquartered in Oulu, in Finland.